NCT01850420

A Study of IMC-1 In Patients With Fibromyalgia

A Double-Blinded, Randomized, Placebo-Controlled, Proof of Concept Phase 2a Study Exploring the Safety and Efficacy of IMC-1 for the Treatment of Patients With Fibromyalgia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 143 (actual)
• Sponsor: Innovative Med Concepts, LLC · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double-blind, placebo-controlled, 16-week study designed to evaluate the hypothesis that tissue-resident herpes virus may be causally related to fibromyalgia symptoms or recurrence. IMC-1 is a combination treatment that is designed to suppress this suspected virus and thus alleviate fibromyalgia symptoms.

Conditions

• Fibromyalgia
• Chronic Pain
• Myofascial Pain

Interventions

Type	Name	Description
DRUG	IMC-1

Timeline

• Start date: 2013-05-01
• Primary completion: 2014-01-01
• Completion: 2014-03-01
• First posted: 2013-05-09
• Last updated: 2015-03-27

Locations

12 sites across 1 country: United States